Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Lymphoma 4Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Breast Neoplasms 2Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hodgkin Disease 1Colonic Neoplasms 1Caregiver Burden 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Health Resources × Clear all
NCT04685551 2022-07-26

Improving Survivorship Among Minority Cancer Dyads

Charles Drew University of Medicine and Science

Phase NA Withdrawn
BreastGastrointestinalThoracic

Caregiver Burden, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡